H3Africa Kidney Disease Research Network- Collaborative Centers

慢性肾病（CKD），包括终末期肾病（CKD 5期），是慢性肾病患者的主要健康问题。 撒哈拉以南非洲（SSA）影响了5000多万人，但遗憾的是缺乏研究数据 也没有迫切需要的预防策略的承诺。SSA中CKD数据的缺乏部分是由于 由于缺乏以人群为基础的CKD流行病学研究和缺乏医生科学家 根据当地优先事项开展CKD的遗传、临床和转化研究。在此，我们建议 利用H3 Africa肾脏疾病研究网络（H3 A-KDRN）（i）进行基因组学，临床和 对最常见的CKD形式进行转化研究;（ii）扩大和支持训练有素的非洲 研究人员和医生科学家根据区域优先事项进行CKD研究;（iii）让SSA参与 社区和研究参与者参与CKD的发起、管理、实施和传播 （四）促进与美国的合作-基础、临床和转化研究人员（包括 散居国外的非洲人），以阐明病因和机制，并发现有效的治疗和 预防性策略，以应对全球非洲血统人群中CKD的巨大负担 H3 A-KDRN是一个研究联盟，最初由以下人员组成：（a）15名学术医学研究人员。 在五个非洲国家设立了中心/大学教学医院-喀麦隆1个、加纳4个、尼日利亚8个、南非 - 1个和坦桑尼亚- 1个;（B）9个北美/以色列研究密集型学术医疗机构;（c）3个共享 核心-培训和职业发展、数据管理和生物统计以及基因分型实验室。 在本申请所要求的五年资助结束时，H3 AKDRN将完成 以下内容： 1.完成三个研究项目：㈠艾滋病毒感染者的慢性肾病; ㈡儿童和青少年 发病肾病综合征和（iii）镰状细胞病肾病。这三项前瞻性队列研究 将有5800名参与者的总样本量。 2.完成四名非洲研究科学家的临床医学博士（n=2）和硕士（n=1）培训 和亚利桑那大学授予的翻译科学（CTS） 3.为45名非洲研究人员完成临床研究方法证书培训 4.建立高效的区域临床和转化研究协调中心， 在SSA进行CKD和其他非传染性慢性病的多中心研究。 有了这些基本目标，H3非洲肾脏病研究网络将产生变革性的影响。 在SSA的CKD研究，从而使我们更接近减少3.52亿人的CKD负担的目标 生活在五个H3 A-KDRN国家的非洲人和全球12亿非洲人后裔。

Chronic kidney disease (CKD) including end stage renal disease (CKD stage 5) is a major health problem in sub-Saharan Africa (SSA) affecting more than 50 million individuals but there is lamentable lack of research data and there is no promise of urgently needed preventative strategies. The lack of data on CKD in SSA are in part due to the absence of population-based epidemiologic studies of CKD and a scarcity of physician scientists conducting genetic, clinical and translational research on CKD according to local priorities. Herein, we propose to leverage the H3Africa Kidney Disease Research Network (H3A-KDRN) to (i) conduct genomics, clinical and translational research on the most prevalent forms of CKD; (ii) expand and support a well-trained cadre of African researchers and physician scientists to conduct CKD research according to regional priorities; (iii) engage SSA communities and research participants in the initiation, governance, implementation and dissemination of CKD research and (iv) foster collaboration with U.S.-based basic, clinical and translational researchers (including Africans in the diaspora) to elucidate etiologies and mechanisms and discover effective therapeutic and preventative strategies to combat the extraordinary burden of CKD in people of African ancestry globally The H3A-KDRN is organized as a research consortium initially composed of: (a) 15 academic medical centers/university teaching hospitals in five African countries- Cameroon - 1, Ghana – 4, Nigeria – 8, South Africa - 1 and Tanzania – 1; (b) 9 North American/Israeli research intensive academic medical institutions; (c) 3 shared cores – Training and Career Development, Data Management and Biostatistics and Genotyping Laboratories. At the end of the five-year funding requested in this application, The H3AKDRN will have accomplished the following: 1. Completion of three research projects on: (i) CKD in HIV-infected patients; and (ii) childhood and adolescent onset nephrotic syndrome and (iii) sickle cell disease nephropathy. These three prospective cohort studies will have a total sample size of 5800 participants. 2. Completion of training of four African-based research scientists toward PhD (n=2) and MSc (n=1) in Clinical and Translational Science (CTS) awarded by the University of Arizona 3. Completion of certificate training in clinical research methods for 45 African-based research personnel 4. Establish a high functioning regional Clinical and Translational Research Coordinating Center to support multicenter research in CKD and other non-communicable chronic diseases in SSA. With these foundational objectives, the H3Africa Kidney Disease Research Network will a transformative impact on CKD research in SSA and thence move us closer to the goal of reducing the burden of CKD in the 352 million Africans living in the five H3A-KDRN countries and in the 1.2 billion people of African descent globally.